東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

Genome-wide CRISPR Screens to Uncove...

Steinhart, Zachary.

Linked to FindBook

Google Book

Amazon

博客來

Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers./
Author:	Steinhart, Zachary.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	222 p.
Notes:	Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
Contained By:	Dissertations Abstracts International81-06B.
Subject:	Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13895481
ISBN:	9781392815434

Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers.
Steinhart, Zachary.

Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 222 p.

Source: Dissertations Abstracts International, Volume: 81-06, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2019.

This item must not be sold to any third party vendors.

Gastrointestinal tract cancers are some of the deadliest cancers and novel therapeutic options are needed. One hallmark of gastrointestinal cancers is the frequent mutation of tumour suppressor genes resulting in constitutive activation of the Wnt-β-catenin signalling pathway. Wnt-β-catenin signalling is a positive regulator of stem cell self-renewal in normal tissues, but cancer cells may take advantage of it to promote their proliferation and survival. Despite frequent cancer cell reliance on Wnt-β-catenin signalling, no clinical therapeutics currently exist that target it. CRISPR/Cas9 gene editing technology has recently allowed for genome-wide loss- of-function screens in vertebrate cells and may therefore be used to identify novel genetic vulnerabilities in human cancer cells. Genome-wide CRISPR screens were completed in RNF43 mutant pancreatic ductal adenocarcinoma (PDAC) cells lines, which rely on Wnt-β- catenin autocrine signaling for their proliferation. These screens revealed a single Frizzled receptor gene out of ten paralogs, FZD5, to be essential for the proliferation of each RNF43 mutant PDAC line. We generated a synthetic human monoclonal antibody specific to FZD5, and found it effective in reducing the growth of RNF43 mutant pancreatic cancers in vitro and in orthotopic xenograft models. We next identified the homeobox transcription factor CDX2 as a context-dependent fitness gene and Wnt-β-catenin transcriptional target in RNF43 mutant pancreatic cancer cells. CDX2 is uniquely overexpressed in Wnt-FZD5 dependent PDAC cells and transcriptome analysis revealed it may drive an intestinal metaplasia phenotype, and may be a suitable biomarker for Wnt-FZD5 dependency. To further identify novel therapeutic targets we completed synthetic-lethal interaction CRISPR screens in cells in which we engineered APC mutations. APC loss of function mutations cause Wnt-β-catenin pathway activation and occur in 80% of colorectal cancers. As a surrogate model for APC mutant colorectal cancer we engineered APC mutant PDAC cell lines to compare with their parental APC wild-type cell lines. Isogenic CRISPR screens comparing these cell lines identified many synthetic-lethal genes, most notably the Aryl Hydrocarbon Receptor (AHR), as a potential druggable vulnerability. Together this work demonstrates the power of genome-wide CRISPR screens for assessing signalling pathways in cancers, and may lead directly to the development of novel targeted therapeutics.

ISBN: 9781392815434Subjects--Topical Terms:

751006
Oncology.
Subjects--Index Terms:

Colorectal cancer

Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers.
LDR:03753nmm a2200397 4500 001 2272596
005 20201105110132.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392815434
035 $a (MiAaPQ)AAI13895481
035 $a AAI13895481
040 $a MiAaPQ $c MiAaPQ
100 1 $a Steinhart, Zachary. $3 3550024
245 1 0 $a Genome-wide CRISPR Screens to Uncover Novel Therapeutic Targets in Wnt-β-catenin Driven Gastrointestinal Cancers.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 222 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisor: Angers, Stephane.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Gastrointestinal tract cancers are some of the deadliest cancers and novel therapeutic options are needed. One hallmark of gastrointestinal cancers is the frequent mutation of tumour suppressor genes resulting in constitutive activation of the Wnt-β-catenin signalling pathway. Wnt-β-catenin signalling is a positive regulator of stem cell self-renewal in normal tissues, but cancer cells may take advantage of it to promote their proliferation and survival. Despite frequent cancer cell reliance on Wnt-β-catenin signalling, no clinical therapeutics currently exist that target it. CRISPR/Cas9 gene editing technology has recently allowed for genome-wide loss- of-function screens in vertebrate cells and may therefore be used to identify novel genetic vulnerabilities in human cancer cells. Genome-wide CRISPR screens were completed in RNF43 mutant pancreatic ductal adenocarcinoma (PDAC) cells lines, which rely on Wnt-β- catenin autocrine signaling for their proliferation. These screens revealed a single Frizzled receptor gene out of ten paralogs, FZD5, to be essential for the proliferation of each RNF43 mutant PDAC line. We generated a synthetic human monoclonal antibody specific to FZD5, and found it effective in reducing the growth of RNF43 mutant pancreatic cancers in vitro and in orthotopic xenograft models. We next identified the homeobox transcription factor CDX2 as a context-dependent fitness gene and Wnt-β-catenin transcriptional target in RNF43 mutant pancreatic cancer cells. CDX2 is uniquely overexpressed in Wnt-FZD5 dependent PDAC cells and transcriptome analysis revealed it may drive an intestinal metaplasia phenotype, and may be a suitable biomarker for Wnt-FZD5 dependency. To further identify novel therapeutic targets we completed synthetic-lethal interaction CRISPR screens in cells in which we engineered APC mutations. APC loss of function mutations cause Wnt-β-catenin pathway activation and occur in 80% of colorectal cancers. As a surrogate model for APC mutant colorectal cancer we engineered APC mutant PDAC cell lines to compare with their parental APC wild-type cell lines. Isogenic CRISPR screens comparing these cell lines identified many synthetic-lethal genes, most notably the Aryl Hydrocarbon Receptor (AHR), as a potential druggable vulnerability. Together this work demonstrates the power of genome-wide CRISPR screens for assessing signalling pathways in cancers, and may lead directly to the development of novel targeted therapeutics.
590 $a School code: 0779.
650 4 $a Oncology. $3 751006
650 4 $a Molecular biology. $3 517296
650 4 $a Cellular biology. $3 3172791
653 $a Colorectal cancer
653 $a CRISPR
653 $a FZD5
653 $a Pancreatic cancer
653 $a RNF43
653 $a Wnt
690 $a 0992
690 $a 0307
690 $a 0379
710 2 $a University of Toronto (Canada). $b Pharmaceutical Sciences. $3 3170825
773 0 $t Dissertations Abstracts International $g 81-06B.
790 $a 0779
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13895481